Market Access Buyer’s remorse: The UK’s VPAG With the ABPI wanting to change the scheme just over a year into its five-year term, it seems that they have buyer’s remorse.
News Trump pledges drug price cuts – and action on 'pill penalty' A Trump executive order aimed at lowering drug prices includes a plan to do away with what industry claims is a flaw in the Inflation Reduction Act.
Sales & Marketing Executing established pharma brand strategy: Key considerati... As blockbuster drug patents edge closer to expiry, pharma companies must rethink how they invest in, support, and scale established brands
News Pharma in a spin as it tries to gauge Trump tariffs impact Pharmaceuticals are exempt from the tariffs revealed by President Donald Trump, for now, but the industry is bracing for what may come next.
News Pharma urges NHS to put medicines at heart of 10-year plan The UK pharma industry has warned that declining access to new medicines in England will undermine the government's efforts to rebuild the NHS.
News Santhera's DMD drug poised for wider rollout in Germany Santhera has agreed pricing and reimbursement for its Duchenne muscular dystrophy drug Agamree with German health funds representing 90% of patients.
R&D Ben Sidders on integrating causality in AI for R&D success Ben Sidders, chief scientific officer at Biorelate, discusses leveraging advanced data science methods to transform the focus and impact of R&D.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face